MOTS-c 10 mg

Peptide Hubs MOTS-c

MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) by Peptide Hubs represents a groundbreaking advancement in mitochondrial peptide research, offered as a 10 mg lyophilized powder in a sterile 2 mL vial. This unique 16-amino acid peptide is encoded within the mitochondrial genome and represents one of the most significant discoveries in mitochondrial biology of the past decade. Manufactured using advanced solid-phase peptide synthesis and rigorously verified through multiple independent laboratory analyses, Peptide Hubs MOTS-c provides researchers with a precisely formulated tool for investigating mitochondrial-nuclear communication, metabolic regulation, and cellular adaptation mechanisms.

MOTS-c Chemical Composition and Structure

Each vial contains 10 mg of high-purity MOTS-c peptide with the following specifications:

• Sequence: H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH
• Molecular Formula: C₁₀₃H₁₅₀N₃₀O₂₂
• Molecular Weight: 2176.49 g/mol
• Purity: >98% confirmed by HPLC analysis
• Form: White lyophilized powder
• Source: Synthetic peptide corresponding to human mitochondrial DNA sequence

Unlike most peptides synthesized from nuclear DNA templates, MOTS-c originates from mitochondrial DNA (position 295 in the 12S rRNA region), giving it unique biological properties and research applications.

Applications and Investigative Benefits

In controlled research settings, MOTS-c presents revolutionary areas of scientific investigation:

• Metabolic Regulation Research: MOTS-c functions as a mitochondrial signal that translocates to the nucleus under metabolic stress, regulating adaptive gene expression related to glucose metabolism, insulin sensitivity, and cellular stress response.
• Exercise Mimetic Studies: Research indicates MOTS-c can induce exercise-like effects, making it valuable for studying muscle adaptation, endurance capacity, and metabolic efficiency without physical activity.
• Aging and Longevity Research: As a mitochondrial-derived peptide, MOTS-c is involved in cellular aging processes, oxidative stress response, and metabolic homeostasis maintenance in aging models.
• Obesity and Metabolic Syndrome Investigations: Studies show MOTS-c can prevent diet-induced obesity and insulin resistance in animal models, positioning it as a key tool for metabolic disease research.

Therapeutic Research Context

While this product is for research use only, previous scientific literature provides important context. According to groundbreaking research published in Cell Metabolism, MOTS-c was identified as a mitochondrial-encoded regulator of metabolic homeostasis that can improve insulin sensitivity and physical performance in mouse models. Further research in Nature Communications demonstrated that MOTS-c treatment in aged mice reversed age-dependent insulin resistance and improved physical performance. These studies establish MOTS-c as a significant mitochondrial signaling molecule with broad implications for metabolic health and aging research.

Dosage Parameters

Important: The following information is derived from published research and should only guide experimental design in appropriate research models. Always consult institutional protocols.

• Standard Research Range: Studies typically use doses of 0.5-5 mg/kg in animal models, administered via intraperitoneal or subcutaneous injection.
• Reconstitution Protocol: Add 2 mL of bacteriostatic water to yield a concentration of 5 mg/mL (5000 mcg/mL). For precise dosing in small models, further dilution may be required.
• Loading Phase: Some protocols initiate with 5 mg/kg daily for 7-10 days to establish metabolic effects.
• Maintenance Phase: Research often continues with 2.5 mg/kg 3 times weekly to sustain metabolic adaptations.
• Administration Timing: Many studies administer MOTS-c 30-60 minutes before metabolic challenges or exercise protocols.

Active Research Life and Pharmacokinetics

MOTS-c exhibits unique pharmacokinetic properties that reflect its mitochondrial origins:

• Half-Life: Approximately 30-45 minutes in research models, with metabolic effects persisting significantly longer
• Onset of Action: Metabolic effects typically observed within 1-2 hours post-administration
• Peak Concentration: Reached within 15-30 minutes following subcutaneous administration
• Duration of Biological Effects: Despite short plasma half-life, metabolic and gene expression changes persist for 24-48 hours
• Tissue Distribution: Demonstrates preferential accumulation in metabolically active tissues (muscle, liver, adipose tissue)
• Clearance: Primarily renal clearance with some enzymatic degradation

Potential Research Observations

Researchers should monitor for expected biological responses consistent with mitochondrial signaling:

• Metabolic Improvements: Enhanced glucose tolerance, improved insulin sensitivity, and altered substrate utilization in metabolic chambers
• Physical Performance Changes: Increased endurance capacity, improved exercise tolerance, and altered fatigue thresholds in exercise models
• Body Composition Modifications: Reduced fat accumulation, prevention of diet-induced obesity, and altered energy expenditure in calorimetry studies
• Cellular Markers: Changes in mitochondrial biogenesis markers (PGC-1α), antioxidant enzyme expression, and stress response pathways
• Minimal Acute Effects: Typically no immediate behavioral changes or obvious physiological disturbances at research doses

Contraindications & Precautionary Measures

This product is for laboratory research use only. Researchers should:

• Not administer to humans or animals for therapeutic purposes
• Exercise caution in studies involving models with mitochondrial disorders or metabolic diseases
• Monitor glucose levels closely in diabetic or insulin-resistant research models
• Use appropriate personal protective equipment during handling and administration
• Conduct research in certified laboratory facilities with proper metabolic monitoring equipment
• Store securely with restricted access to prevent unauthorized use
• Dispose of materials according to institutional biohazard and chemical waste protocols
• Consult with institutional biosafety committees when designing studies involving mitochondrial peptides

Overdose

Administration significantly above established research parameters may produce exaggerated metabolic effects including hypoglycemia, altered thermogenesis, or disrupted energy homeostasis that could compromise animal welfare and study validity. Researchers should establish careful dose-escalation protocols and monitor metabolic parameters closely. Emergency procedures should include glucose monitoring and supportive care capabilities for research models experiencing metabolic disturbances.

MOTS-c Stack/Cycle Integration

For comprehensive metabolic and performance research, MOTS-c may be studied alongside other Peptide Hubs products in controlled experimental designs. Researchers might investigate combinations such as:

• PE 22-28: For synergistic research on glucose metabolism and insulin signaling pathways in metabolic disease models.
• AOD 9604: In studies comparing different mechanisms of fat metabolism and metabolic regulation.
• Chonluten: For research on combined effects on cellular stress response and tissue protection mechanisms.
• Epitalon 25 mg: In investigations of combined anti-aging and metabolic effects in aging research models.

These research combinations should only be conducted by qualified investigators following appropriate experimental designs, ethical guidelines, and institutional approvals, with particular attention to metabolic monitoring and animal welfare considerations.

Package Presentation

Each research unit arrives in specialized pharmaceutical packaging designed for peptide stability:

• One sterile amber glass vial with fluoropolymer-coated stopper containing 10 mg lyophilized MOTS-c
• Oxygen-absorbing packet to prevent oxidative degradation during shipping
• Tamper-evident holographic seal ensuring product integrity
• Dual lot numbers and expiration dates (18 months from manufacture)
• Complete certificate of analysis package from two independent laboratories
• Product insert with detailed handling, storage, and stability information

Storage & Stability Protocols

Due to its mitochondrial peptide structure, MOTS-c requires specific storage conditions:

• Unreconstituted: Store at -20°C (-4°F) in original packaging. For short-term storage (up to 30 days), 2-8°C (36-46°F) is acceptable. Protect from light and oxygen exposure.
• Reconstituted: Use immediately in research applications. If necessary, store at 2-8°C (36-46°F) for no more than 24 hours while maintaining sterility.
• Freezing Reconstituted Solution: Not recommended as freeze-thaw cycles may disrupt peptide structure.
• Handling: Minimize exposure to room temperature. Reconstitute quickly and return unused portions to cold storage immediately.
• Stability: Properly stored lyophilized powder maintains stability for 18 months. Monitor for color changes indicating oxidation.

MOTS-c Research Referrers

The discovery of MOTS-c represents a paradigm shift in understanding mitochondrial biology and inter-organelle communication. As one of the first identified mitochondrial-derived peptides (MDPs) with clear hormonal functions, MOTS-c bridges mitochondrial stress response with nuclear gene regulation. Its ability to translocate from mitochondria to nucleus under metabolic stress conditions creates a unique research model for studying cellular adaptation mechanisms. Peptide Hubs maintains exceptional quality standards for this advanced research peptide, as demonstrated by dual laboratory verifications showing 11.50 mg (115% of labeled amount, January 2026) and 9.73 mg (97.3%, October 2025) results. This commitment to transparency and accuracy ensures researchers receive materials of precisely documented composition for groundbreaking mitochondrial and metabolic research.

Third-Party Laboratory Verification

Peptide Hubs MOTS-c undergoes rigorous dual laboratory testing to ensure exceptional quality and accuracy for research applications:

January 12, 2026

View Result

11.50 mg / 10 mg

October 1, 2025

View Result

9.73 mg / 10 mg

Dual independent laboratory analyses confirm the exceptional quality of Peptide Hubs MOTS-c. The January 12, 2026 test shows 11.50 mg content (115% purity), while the October 1, 2025 test confirms 9.73 mg content (97.3% purity). These results demonstrate consistent batch-to-batch quality and our commitment to providing researchers with accurately dosed materials for mitochondrial and metabolic research.